IQVIA Announces Launch of Clinical Trial Financial Suite, a Next-Generation Platform for Integrated Financial Management
IQVIA (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today announced the launch of its Clinical Trial Financial Suite (CTFS), an AI-enabled platform orchestrating all financial aspects of clinical trials. CTFS is designed to eliminate inefficiencies created by siloed systems and fragmented processes. In contrast to other industry offerings, CTFS unifies budgeting, contracting, forecasting and payment workflows with shared data and end-to-end processes.
The suite's first module, CTFS Site Payments, brings end-to-end automation to one of the most complex trial processes. By leveraging agentic AI to set up budgets, process invoices and identify anomalies, the module frees up financial teams from repetitive manual tasks to focus their attention more productively.
IQVIA's technology and operations experts behind CTFS have supported site and participant payments across more than 200 geographies. The solution uses advanced technology to deliver enterprise-grade scalability and security, while deploying AI to drive efficiency and acceleration to the most manual and burdensome processes. Projected customer outcomes include up to 50% reduction in processing time.
"With CTFS, we are building the financial backbone for modern clinical trials — unified, globally scalable and powered by agentic AI," said Bernd Haas, Senior Vice President, Digital Products & Solutions at IQVIA. "From protocol to payments, we're connecting and simplifying financial processes into a seamless, transparent experience for sponsors, CROs and study sites alike."
CTFS Site Payments is slated for general commercial availability in Q1 2026, following a Q4 2025 sandbox release where early adopters will pilot the solution against their business and collaborate on their future needs.
To learn more about CTFS or CTFS Side Payments visit Clinical Trial Financial Suite - IQVIA
About IQVIA
IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA's portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using AI responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 90,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA's insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.
IQVIAFIN
View source version on businesswire.com: https://www.businesswire.com/news/home/20250910634240/en/
Kerri Joseph, IQVIA Investor Relations ([email protected])
+1.973.541.3558
Alissa Maupin, IQVIA Media Relations ([email protected])
+1.919.923.6785